# Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia

> **NCT00825539** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 68 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** AQW051
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00825539
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2020-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00825539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00825539, "Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00825539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*